Abstracts tagged "Scleroderma"

Abstract Number: 786 • 2012 ACR/ARHP Annual Meeting
Crosstalk Between Integrins and TGFβ in the Pathogenesis and Treatment of Multiple Presentations of Scleroderma
Elizabeth E. Gerber¹, Fredrick M. Wigley², Elaine C. Davis³, David L. Huso⁴ and Harry C. Dietz¹, ¹Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Department of Anatomy and Cell Biology, McGill University, Montreal, QC, Canada, ⁴Comparative Pathology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Scleroderma, defined as pathologic fibrosis of the skin, has many clinical presentations. In the most commonly recognized form, systemic sclerosis (SSc), previously healthy individuals…
Abstract Number: 693 • 2012 ACR/ARHP Annual Meeting
A Placebo-Controlled Phase II Study of Hyperimmune Caprine Serum in Diffuse Cutaneous Systemic Sclerosis: Safety and Potential Efficacy
Niamh P. Quillinan¹, Deirdre McIntosh², Syed Haq² and Christopher P. Denton¹, ¹Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United Kingdom, ²Daval International Ltd, Eastbourne, East Sussex, United Kingdom
Background/Purpose: We have performed a study to explore safety and tolerability of hyperimmune caprine serum (AIMSPRO®) prepared under GMP conditions in established diffuse cutaneous systemic…
Abstract Number: 697 • 2012 ACR/ARHP Annual Meeting
Demographic, Clinical, Serologic and Socioeconomic Measures Each Predict Mortality in Scleroderma
Allan C. Gelber¹, Rebecca L. Manno², Adrianne Woods¹, Ami A. Shah³, Francesco Boin³, Laura K. Hummers³ and Fredrick M. Wigley³, ¹Medicine/ Rheumatology, Johns Hopkins University, Baltimore, MD, ²Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ³Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Multivariate Model 1 Adjusted RR 95%CI Multivariate Model 2 Adjusted RR 95%CI Male vs Female 1.4 1.1 – 1.9 Male vs Female 1,4…
Abstract Number: 708 • 2012 ACR/ARHP Annual Meeting
Histological Features of Localized Scleroderma‘en Coup De Sabre‘: A Study of 16 Cases
Takashi Taniguchi, Yoshihide Asano, Zenshiro Tamaki, Kaname Akamata, Naohiko Aozasa, Shinji Noda, Takehiro Takahashi, Yohei Ichimura, Tetsuo Toyama, Miki Sugita, Hayakazu Sumida, Yoshihiro Kuwano, Miki Miyazaki, Koichi Yanaba and Shinichi Sato, Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan
Background/Purpose: Scleroderma is a chronic disease of unknown etiology characterized by skin fibrosis and is divided into two clinical entities: localized scleroderma and systemic sclerosis.…
Abstract Number: 709 • 2012 ACR/ARHP Annual Meeting
Fingertip Skin Hardness in Limited Scleroderma: Durometry versus Manual Assessment
Thomas Osborn¹, Eric L. Matteson¹, Floranne Ernste², Cynthia S. Crowson³, Deana D. Hoganson⁴ and Irene Z. Whitt⁵, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Division of Rheumatology, Mayo Clinic Rochester, Rochester, MN, ³Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ⁴Rheumatology, Mercy Arthritis and Osteoporosis Center, Urbandale, IA, ⁵NIH/NIEHS/Environmental Autoimmunity Group, Bethesda, MD
Background/Purpose: Skin manifestations of scleroderma involve the digits in nearly all patients. Assessment of change at the level of digital skin involvement is difficult. The Modified…
Abstract Number: L14 • 2012 ACR/ARHP Annual Meeting
Treatment of Diffuse Systemic Sclerosis Patients with Anti-Transforming Growth Factor-Beta, Fresolimumab, Inhibits Transforming Growth Factor-Beta-Regulated Gene Expression in Skin and Is Associated with a Rapid Decline in Skin Score
Robert Lafyatis¹, Sashidhar Nakerakanti², Allison Mathes², Cristina Padilla², Sarah McLaughlin³, Michael R. York², Giuseppina Farina⁴, Romy Christmann¹, Richard P. Polisson⁵ and Robert W. Simms¹, ¹Rheumatology, Boston University School of Medicine, Boston, MA, ²Rheumatology, Boston University Medical Center, Boston, MA, ³Division of Rheumatology, Boston University Medical Center, Boston, MA, ⁴Arthritis center, Boston University, Boston, MA, ⁵Sanofi-Aventis US, Cambridge, MA
Background/Purpose: Transforming growth factor-beta (TGFb) has long been suspected to mediate fibrotic signals in systemic sclerosis (SSc) as it potently stimulates collagen deposition in vitro,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].